AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2023
Jan 4, 2023
6965_dirs_2023-01-04_367d9833-85be-4f1e-bb42-d8cbe2571ca7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2023-01-03
Reporting Person: Rabinowitz Michael (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-03 | Common Stock | S | 1425 | $13.0132 | Disposed | 138043 | Direct |
| 2023-01-03 | Common Stock | S | 11900 | $12.4917 | Disposed | 126143 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.